Genetic correction of induced pluripotent stem cells mediated by transcription activator-like effector nucleases targeting ALPL recovers enzyme activity and calcification in vitro

• Published in: Molecular genetics and metabolism Vol. 127; no. 2; pp. 158 - 165
• Main Authors: Nakano, Chiho, Kitabatake, Yasuji, Takeyari, Shinji, Ohata, Yasuhisa, Kubota, Takuo, Taketani, Ken, Kogo, Mikihiko, Ozono, Keiichi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2019
• Subjects: Alkaline phosphatase; Alkaline Phosphatase - genetics; Alkaline Phosphatase - metabolism; Biopsy; Calcification, Physiologic; Cells, Cultured; Female; Gene Editing; Gene Targeting - methods; Gene therapy; Genome editing; Humans; Inborn error; Induced Pluripotent Stem Cells - enzymology; Male; Metabolic bone disease; Mutagenesis, Site-Directed; Mutation; Osteoblasts - physiology; Phenotype; Skin - pathology; Transcription Activator-Like Effector Nucleases - genetics; Alkaline phosphatase; Genome editing; Gene therapy; Metabolic bone disease; Inborn error
• ISSN: 1096-7192; 1096-7206
• DOI: 10.1016/j.ymgme.2019.05.014

Hypophosphatasia (HPP) is an inheritable disease affecting both skeletal systems and extra-skeletal organs due to mutations of the gene ALPL, which encodes tissue-nonspecific alkaline phosphatase. Recently, an enzyme replacement therapy using asfotase alfa was developed to ameliorate the complications of HPP. However, it requires frequent injections and is expensive to maintain. As an alternative, cell and gene therapy using human induced pluripotent stem cells (iPSCs) after precise correction of the mutation is feasible due to advances in genome-editing technology. In the study, we examined the alkaline phosphatase (ALP) activity and calcification in vitro of two childhood HPP patient-derived iPSCs after the correction of the c.1559delT mutation, which is the most frequent mutation in Japanese patients with HPP, using transcription activator-like effector nucleases (TALENs). The gene correction targeting vector was designed for site-directed mutagenesis using TALEN. After selection with antibiotics, some clones with the selection cassette were obtained. Gene correction was confirmed by Sanger sequencing. The mutation was corrected in one allele of ALPL in homozygous patients and compound heterozygous patients. The correction of ALPL did not result in an increase in ALP when the selection cassette remained. Conversely, iPSCs exhibited ALP activity after the elimination of the cassette using Cre/LoxP. The quantitative analysis showed the half ALP activity in corrected iPSCs of that of control iPSCs, corresponding to heterozygous correction of the mutation. In addition, osteoblasts differentiated from the corrected iPSCs exhibited high ALP activity and some calcification in vitro. Moreover, the osteoblast-like phenotype was confirmed by increased expression of osteoblast-specific genes such as COL1A1 and osteocalcin. These results suggest that gene correction in iPSCs may be a candidate treatment for HPP patients.